News & Press

Press Releases

Keyword search
Year
Abbisko and Allist Pharmaceuticals Jointly Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer
May 09,2024
Abbisko Therapeutics Announces Irpagratinib, an Innovative FGFR4 inhibitor,has been Granted ODD by the U.S. FDA for the Treatment of HCC
Apr 25,2024
2024 AACR | Abbisko Therapeutics Presented 3 Pre-clinical Research Results with Oral and Poster Presentations
Apr 10,2024
Abbisko Therapeutics Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib(ABSK021)
Apr 09,2024
2024 AACR | Abbisko Therapeutics will present 3 pre-clinical research results with oral presentation and posters
Mar 07,2024
2024 ESMO TAT Oral Presentation — Abbisko Therapeutics presented preliminary first-in-human trial results of its selective FGFR2/3 inhibitor ABSK061
Feb 28,2024
Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112
Feb 23,2024
Merck Delegation Visited Abbisko Shanghai R&D Center
Feb 07,2024
US$70 million Arrived! Abbisko Therapeutics Announced it Received Upfront Payment Pursuant to the Licensing Agreement for Pimicotinib (ABSK021) with Merck
Feb 06,2024
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021)
Jan 09,2024
Abbisko Therapeutic Completed the First Patient Dose in Phase I Clinical Trial for Novel Small Molecule CD73 Inhibitor ABSK051
Jan 03,2024
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib(ABSK021)
Dec 14,2023
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
Dec 05,2023
Abbisko Therapeutics Completes the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor - Pimicotinib (ABSK021) in China
Nov 28,2023
Abbisko Therapeutic announces the IND approval by China NMPA for novel small molecule CD73 inhibitor ABSK051
Nov 09,2023
Abbisko Therapeutics Obtained Approval from U.S. FDA to Conduct First-in-Human (FIH) Clinical Study of A Next-Generation FGFR4 Mutant Inhibitor ABSK012
Nov 08,2023
Abbisko presented two clinical updates of Pimicotinib(ABSK021)at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Nov 03,2023
Abbisko will present two clinical updates of Pimicotinib(ABSK021)at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Oct 30,2023
Abbisko Therapeutic announces the IND approval by China NMPA for its next-generation EGFR-Exon20ins inhibitor ABSK112
Oct 27,2023
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology(ESMO)
Oct 17,2023
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
Oct 16,2023
Abbisko Therapeutics Obtains Approval from U.S. FDA to Conduct Phase I Clinical Study of FGFR4 Inhibitor Irpagratinib (ABSK011)
Sep 25,2023
Abbisko is going to disclose two pre-clinical research results at the 35th EORTC-NCI-AACR Conference
Sep 20,2023
Abbisko Therapeutics published breakthrough translational research results of FGFR4 inhibitors on an AACR journal “Molecule Cancer Therapeutics”
Sep 18,2023
Abbisko Therapeutics Obtained Approval from Europe EMA for Pivotal Global Multi-Center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)
Sep 11,2023
VOLUNTARY ANNOUNCEMENT THE SHAREHOLDING OF THE FOUNDERS OF THE COMPANY
Aug 29,2023
Milestone — Abbisko Therapeutics Completes the First Patient Dose in US Phase III TGCT Trial of in CSF-1R Inhibitor – Pimicotinib(ABSK021)
Aug 02,2023
Abbisko will present clinical results of two First-in-Human Studies at the 2023 European Society for Medical Oncology(ESMO)
Jul 31,2023
Abbisko Therapeutic announces the IND approval by U.S. FDA for its next-generation EGFR-Exon20 inhibitor ABSK112
Jul 05,2023
Abbisko Therapeutics Announces First Patient Dosed in Phase II Trial of CSF-1R Inhibitor – Pimicotinib(ABSK021)for cGVHD.
Jun 12,2023
Abbisko Therapeutics announces that Europe EMA has granted Priority Medicine designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
Jun 08,2023
Abbisko to present updated Phase Ib clinical results of Pimicotinib (ABSK021)in patients with advanced TGCT at the 2023 ASCO annual meeting
May 29,2023
Abbisko Therapeutics Completes the First Patient Dose in Global Phase III Trial of CSF-1R Inhibitor – Pimicotinib(ABSK021)
Apr 27,2023
Abbisko presents 5 research results at the 2023 AACR Annual Meeting
Apr 17,2023
Abbisko Therapeutic announces that its next-generation FGFR4 mutant inhibitor ABSK012 has been granted orphan drug designation in the US for the treatment of Soft Tissue Sarcoma
Apr 03,2023
Abbisko Therapeutics Obtained Approval from U.S. FDA for Pivotal Global Multi-center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)
Mar 16,2023
Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376
Mar 01,2023
Abbisko therapeutic announces the IND approval by NMPA for its next-generation FGFR inhibitor ABSK121
Feb 22,2023
EXPANDED ACCESS POLICY
Feb 01,2023
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
Jan 30,2023
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021)in cGVHD
Jan 17,2023
Abbisko Therapeutics announces preliminary Phase I safety and efficacy results of Irpagratinib (ABSK011) in patients in second-line hepatocellular carcinoma with FGF19 overexpression
Dec 15,2022
Abbisko Therapeutics announces preliminary Phase II safety and efficacy results of Fexagratinib (ABSK091) in patients with urothelial carcinoma
Dec 08,2022
Preliminary Phase Ib results of ABSK021 for advanced TGCT will be published at the 2022 CTOS annual meeting
Nov 15,2022
Abbisko Therapeutics completed the first patient enrollment in the Phase II clinical trial for ABSK091 in combination with BeiGene’s Tislelizumab in urothelial carcinoma
Nov 04,2022
Abbisko Therapeutic announces the clinical trial approval granted by U.S. FDA for its next-generation FGFR inhibitor ABSK121
Nov 01,2022
Abbisko Therapeutics obtained pivotal Phase III clinical trial approval for CSF-1R inhibitor ABSK021 from the CDE of NMPA
Oct 25,2022
Abbisko Therapeutics Completed Dosing of First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043
Sep 27,2022
Abbisko Therapeutics won the 2022 "Future Star" Award of the biopharmaceutical industry
Aug 15,2022
Abbisko Therapeutics announces China NMPA breakthrough therapy designation granted for its CSF-1R inhibitor ABSK021
Jul 20,2022
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
Jul 04,2022
Abbisko Therapeutics Announces the Appointment of Dr. Zidong Zhang as CFO
May 16,2022
Abbisko Therapeutics Declared Two Next-Generation Precision Oncology Preclinical Candidates and Will Present Multiple Discovery and Translational Research Results at AACR Annual Meeting 2022
Mar 11,2022
Abbisko Therapeutics Has Obtained IND Approval for ABSK061, an Innovative and Highly Selective FGFR2/3 Inhibitor, from the NMPA
Mar 03,2022
Abbisko Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate ABSK091 in Combination with Tislelizumab
Feb 15,2022
Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody
Feb 08,2022
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
Jan 18,2022
Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Study for FGFR Inhibitor ABSK091 (AZD4547) in Urothelial Cancer
Dec 02,2021
Abbisko Therapeutics Completes Dosing of the First Subject in the Dose Expansion Part of Phase I Trial for CSF-1R Inhibitor ABSK021
Nov 17,2021
Abbisko’s Partner X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
Nov 03,2021
Abbisko Therapeutics R&D and Manufacturing Facility Landed in Zhangjiang
Oct 29,2021
Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK061, A Selective Inhibitor of FGFR2 and FGFR3, by the U.S. FDA
Oct 25,2021
Abbisko Therapeutics Announces the IND Approval by NMPA for Phase II Clinical Trial of ABSK011
Oct 19,2021
Abbisko Cayman Limited successfully landed on the Hong Kong Stock Exchange
Oct 15,2021
Abbisko Therapeutics Announces Dosing of First Patient in A Phase I Clinical Study of ABSK043 In Australia
Sep 03,2021
Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia
Jul 12,2021
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
Jul 05,2021
Abbisko Therapeutics Announces Dosing of First Patient in A Phase Ib Clinical Study of ABSK011 In China
Jun 29,2021
Abbisko Therapeutics Announces the Appointment of Mr. Yongyi Li as General Counsel
Jun 04,2021
Abbisko Therapeutics Announces the Appointment of Ms. Jia Feng as Executive Director and Head of Human Resource
Jun 04,2021
Abbisko Therapeutics and AstraZeneca China Announce Strategic Partnership
May 25,2021
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
Apr 29,2021
Abbisko Therapeutics Announces the Appointment of Dr. Zhen Zhang as CMC VP
Apr 19,2021
Abbisko Therapeutics Announces the Appointment of Dr. Jing Ji as Chief Medical Officer
Feb 18,2021
Abbisko Therapeutics Featured at the 39th Annual J.P. Morgan Healthcare Conference
Jan 19,2021
Abbisko Therapeutics Announces the Appointment of Dr. Xie Kewei as Chief Business Officer
Jan 12,2021
Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by The Carlyle Group
Jan 08,2021
Abbisko Therapeutics Announces the Appointment of Mr. Ye Lin as Chief Financial Officer
Nov 16,2020
Abbisko Therapeutics Obtained ABSK021 IND Approval in China
Oct 29,2020
Abbisko Therapeutics Obtained IND approval for Phase 1b/II Clinical Trial of Mavorixafor in Combination with Toripalimab in China
Sep 09,2020
Abbisko Therapeutics Announces $70M Series C Financing Led by Temasek
Mar 25,2020
Abbisko Therapeutics Announces Receiving of the IND Approval by the China NMPA for ABSK-011, A Novel FGFR4 Inhibitor
Mar 09,2020
Abbisko Therapeutics Announces the IND Approval of a Novel FGFR4 Inhibitor ABSK011 by the Taiwan FDA
Dec 06,2019
Abbisko Therapeutics Announces Initiation of Phase 1 Trial for ABSK021, its Selective CSF-1R Small Molecule Inhibitor
Aug 19,2019
X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater China
Jul 17,2019
Abbisko Therapeutics Wins the Zhangjiang Science City Innovation & Progress Award for Outstanding Enterprises
Jan 18,2019
Abbisko Therapeutics is Awarded as One of the Most Promising Enterprises Founded by Foreign-educated Returnees
Dec 23,2018
Shanghai Mayor Ying Yong Presents Abbisko Therapeutics with “MNC’s R&D Centers” Certificate
Dec 07,2018
Dr. Hongping Yu Attends and Delivers a Speech at ACS Conference
Oct 28,2018
Abbisko Wins the Best Biomedical Investment Case Award in the Healthcare Investment Rankings 2018
Mar 30,2018
Dr. Yao-chang Xu Attends the Hong Kong Biotech Summit 2018
Mar 23,2018
Dr. Yao-chang Xu Presents at the BIO Asia International Conference
Mar 21,2018
Dr. Zhui Chen Attends China Healthcare Investment & Partnering Symposium 2018 on Invitation
Mar 16,2018
Dr. Yao-chang Xu Attends Zhangjiang League of Makers Health Industry Association’s Inauguration
Nov 20,2017
Dr. Yao-chang Xu Gives a Lecture at Peking University Clinical Research Institute
Apr 06,2017
Abbisko Completes Series A Round Financing of $ 28 Million
Feb 05,2017
Dr. Hongping Yu Attends a Teach-in at Nankai University on Invitation
Nov 24,2016
Dr. Yao-chang Xu Attends Bank of America Merrill Lynch China Annual Conference 2016 and Delivers a Speech
Nov 01,2016

Tel:(+86) 021-68912098

E-Mail:Bd@abbisko.com
    PR@abbisko.com
    IR@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1    PRIVACY POLICY